Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform by C. Prontera et al.
Clin Chem Lab Med 2014; aop
 *Corresponding author: Prof. Aldo Clerico,  MD, Department 
of Laboratory Medicine, Fondazione CNR-Regione Toscana G. 
Monasterio, Scuola Superiore Sant ’ Anna, Via Moruzzi 1, 56126 
Pisa, Italy, Phone:  + 39 0585 493569, Fax:  + 39 0585 493601, 
E-mail:  clerico@ftgm.it ; and  Scuola Superiore Sant ’ Anna, Pisa, Italy 
 Concetta Prontera, Michele Emdin and Claudio Passino:  Fondazione 
CNR-Regione Toscana G. Monasterio, Pisa, Italy 
 Silvia Masotti and Maria Franzini:  Scuola Superiore Sant ’ Anna, 
Pisa, Italy 
 Gian Carlo Zucchelli:  QualiMedLab Spin-Off dell ’ Istituto di Fisiologia 
Clinica del CNR, Pisa, Italy 
 Letter to the Editor 
 Concetta  Prontera ,  Silvia  Masotti ,  Maria  Franzini ,  Michele  Emdin ,  Claudio  Passino , 
 Gian Carlo  Zucchelli and  Aldo  Clerico * 
 Comparison between BNP values measured in 
capillary blood samples with a POCT method and 
those measured in plasma venous samples with 
an automated platform 
 DOI 10.1515/cclm-2014-0873 
 Received  September  1 ,  2014 ; accepted  October  2 ,  2014 
 Keywords:  brain natriuretic peptide (BNP);  immunoassay; 
 natriuretic peptides;  point of care testing (POCT) methods. 
 To the Editor, 
 Brain natriuretic peptide (BNP) assay is recommended as 
the first line biomarker for diagnosis, prognosis and man-
agement of patients with heart failure (HF)  [1, 2] . A recent 
pilot study reported that BNP assay at home, using a novel 
finger-stick technology, may be useful for early detection 
of decompensation, driving quick adjustments of treat-
ment regimen, and decreasing repeated hospitalization of 
HF patients  [3] . However, at the present time, there are no 
published data demonstrating that BNP values measured 
in capillary blood samples are comparable to those meas-
ured in venous plasma samples with fully automated BNP 
immunoassay methods. Therefore, the aim of the present 
study is to compare some analytical characteristics and 
clinical results found with the Heart Check Alere Test Strip 
(Alere Tchnologies Limited, Stirling, Scotland) for the BNP 
assay in finger-stick blood samples to those observed with 
the automated Alere Triage BNP BCIS method, using the 
automated UniCel DxI 800 platform (Beckman Coulter, 
Inc, Fullerton, CA, USA). 
 The Alere Heart Check Test Strip is a point of care 
testing (POCT) immunoassay to be used with the Alere 
Heart Check Meter for the measurement of BNP using 
fresh capillary whole blood  [4] . Following insertion of 
the test strip into the meter, a drop of finger-stick blood 
is applied to the test strip, and the meter analyzes the 
sample and determines the BNP concentration, which can 
be transmitted through a wireless connection mechanism 
to a target location. The immunoassay is a direct, one-step 
sandwich immunoassay, which uses a biotinylated anti-
BNP monoclonal antibody bound to streptavidin coated 
magnetic solid phase particles  [4] . The range of the BNP 
assay is 10 – 4955 ng/L with a limit of blank of 8.7 ng/L  [4] . 
 The POCT method reproducibility (n = 10) was evalu-
ated with two control EDTA samples, provided as calibra-
tors by the manufacturer. The first control sample showed 
a mean value of 185.5 ± 25.1 ng/L (CV 13.6%) and the second 
one 1722.1 ± 291.9 ng/L (CV of 16.9%); these data are well 
in agreement to those reported by the manufacturer  [4] . 
Moreover, two EDTA plasma samples of HF patients, 
repeatedly assayed, using two different lots of calibrators, 
showed a reproducibility of 7.1% (93.3 ± 6.7 ng/L, n = 21) and 
16.4% (1163.3 ± 190.7 ng/L, n = 15), respectively. 
 The BNP values observed with this POCT method 
were compared with those measured with the Alere Triage 
BNP BCIS method using the automated UniCell DxI 800 
platform  [5] . We measured 88 fresh finger-stick samples 
of capillary whole blood and EDTA plasma samples of 
healthy adult subjects and patients diagnosed with sys-
tolic HF. We also measured two plasma control samples 
collected from patients with HF and eight control samples 
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distributed in the multicenter CardioOrmoCheck study 
with both methods ( Table 1 ). The CardioOrmocheck study 
is a proficiency testing study for the measurement of BNP 
and NT-proBNP, organized in Italy since 2005, as previ-
ously reported in detail  [6 – 8] . The Passing-Bablok plot 
between the 98 BNP values measured with the DxI 800 
platform (considered as the reference method) are reported 
in  Figure 1 A. Moreover, a very close linear regression was 
observed using the log-transformed BNP values measured 
by these two methods (POCT method = 0.135 + 0.956 log-DxI 
platform, R = 0.956, n = 98). The mean ( ± SD) percent dif-
ference between the values found with the two methods 
[(POCT – DxI)/DxI × 100] was of 14.9 ± 40.5% (p = 0.0404 by 
Wilcoxon-signed rank test for bias between methods). 
Finally, the Bland-Altman plot suggests that there is only 
a trend (p = 0.0543) for the presence of a proportional bias 
between these two methods ( Figure 1 B). 
 The mean ratio between the values measured with 
the POCT method and the DxI platform in the two EDTA 
plasma samples of HF patients and the eight plasma 
control samples were not significantly different to the 
mean ratio found in the remaining 88 capillary blood 
samples (1.134 ± 0.405 vs. 1.283 ± 0.508, p = 0.4181 by Mann-
Whitney U-test). 
 In conclusion, our data suggest that it is possible 
to measure BNP in fresh finger-stick samples of capil-
lary whole blood with an acceptable reproducibility, 
and within 10 – 20  min to obtain results close correlated 
to those measured by the automated platform in plasma 
blood samples collected from a vein. The measurement 
of BNP in fresh finger-stick samples of capillary whole 
blood with this POCT method is in particular indicated for 
the management of HF patients at home and for the BNP 
assay in neonates and children. 
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 Figure 1   Passing-Bablok and Bland-Altman plots. 
 (A) Passing-Bablok agreement test between the BNP values meas-
ured with the DxI 800 platform (X-axis, considered as the reference 
method) and the POCT method in 98 samples collected from healthy 
subjects and patients with heart failure. The slope of linear regression 
was 1.051 (confidence 95% range 0.961 – 1.154) and the intercept 3.87 
ng/L (range  – 3.49 to 11.41 ng/L). The dotted line indicates the identity 
relationship (Y = X). (B) Bland-Altman plot reporting in the X-axis the 
mean of BNP values measured by the POCT method and DxI platform, 
while in the Y-axis the difference between the value measured by POCT 
method and DxI platform, respectively. The linear regression found 
between the values of X and Y variables is also indicated by a continu-
ous line [Y(difference) = – 17.593 + 0.089X(mean); p = 0.0543]. 
 Table 1   BNP values (ng/L) measured with the POCT method in the 
authors ’ laboratory and those found by laboratory participant to the 
external quality assessment scheme CardioOrmoCheck using the 
automated DxI platform in eight control samples distributed in the 
2014 cycle. 
Control 
sample 
  POCT method, 
ng/L 
  Automated 
platform, ng/L 
  Ratio 
41a   264.5   172.3   1.54
41b   161.5   129.6   1.25
42a   194.0   179.3   1.08
42b   183.0   138.3   1.32
43a   203.5   208.8   0.98
43b   155.0   141.6   1.09
44a   172.0   171.7   1.00
44b   179.0   185.6   0.96
Mean ± SD   189.1 ± 34.4   165.9 ± 27.1   1.15 ± 0.20 
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